HSK 44459
Alternative Names: HSK-44459Latest Information Update: 03 Apr 2026
At a glance
- Originator Haisco Pharmaceutical Group
- Class Anti-inflammatories; Antifibrotics; Skin disorder therapies
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Atopic dermatitis
- Phase I Idiopathic pulmonary fibrosis
Most Recent Events
- 31 Mar 2026 Haisco Pharmaceutical Group plans a phase III trial for Pulmonary fibrosis in April 2026 (PO, Tablet) (NCT07503587)
- 02 Sep 2025 Haisco Pharmaceutical plans a phase II trial for Plaque psoriasis in China (PO) in September 2025 (NCT07150988)
- 17 Jul 2025 Haisco Pharmaceutical plans a phase II trial for Behcet's-syndrome (Treatment experienced) in July 2025 (PO) (NCT07070739)